MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why STTK Stock slipped -1.46% Today — RQD Quant Desk Flash
$5.72 -1.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.69
Shattuck Labs Inc. (STTK) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $574.1M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.69 (-0.45%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STTK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY STTK SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$5.97-9.2% Next Q
39
Q2 (-2Q)Grade E$5.42+1.3% Next Q
36
Q3 (-1Q)Grade E$5.49+4.2% Next Q
34
CurrentGrade E$5.72-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a STTK Turnaround Squeeze
While STTK currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.28) and Max Pain ($6.01) forces dealer call-delta covering toward $8.75.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $STTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “STTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why STTK Stock slipped -1.46% Today — RQD Quant Desk Flash
Shattuck Labs Inc. (STTK) slipped -1.46% to $5.72, trading at 61% of its 52-week range ($1.72 – $8.33). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 61% of its 52-week range ($1.72 – $8.33) with RSI-14 at 43.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.72 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live STTK Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STTK)
- ✓Walkthrough of STTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
STTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.00%📐 HORIZONTAL RANGE
2026-10-30O $5.67H $5.74L $5.36C $5.72VOL 951.5K
RES: $8.87SUP: $5.03SMA50: $6.28SMA200: $6.04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
STTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on STTK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for STTK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for STTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STTK)
Health Care Rank #915 of 1016
⚔️ NGNE vs STTK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (STTK vs. NGNE, EVO, ACRS, DRUG)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Shattuck Labs Inc. (STTK) ranks #915 by composite RQD confidence (31/100, grade E) and #428 by equity capitalization ($574.1M). Within this direct 5-issuer industry benchmark cohort, STTK leads on earnings valuation at N/A trailing P/E, while STTK leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. DRUG currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with STTK at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STTK
ACTIVE
Shattuck Labs Inc. | E | 31/100 | — | — | -35.0% | -1.46% | $574.1M | Benchmark Subject |
| NGNE Neurogene Inc. | D- | 36/100 | — | — | -35.0% | -5.26% | $576.7M | /ngne-vs-sttk → |
| EVO Evotec SE | D+ | 57/100 | — | — | — | -1.56% | $562.1M | /evo-vs-sttk → |
| ACRS Aclaris Therapeutics Inc. | E | 31/100 | — | 73.3% | -35.0% | +0.76% | $587.3M | /acrs-vs-sttk → |
| DRUG Bright Minds Biosciences Inc. | C- | 61/100 | — | — | — | +2.48% | $556.7M | /drug-vs-sttk → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680367In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shattuck Labs Inc. (STTK) reported GAAP revenue of $1.0M (-82.5% vs. FY2024 revenue of $5.7M , and -39.6% cumulative change since FY2023) , GAAP net income of -$48.8M, operating cash flow of -$39.9M, and free cash flow of -$40.0M (+34.0% YoY). On the balance sheet, STTK closed FY2025 with $91.0M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.0M | -$48.8M | -$39.9M | -$40.0M | $91.0M | — |
| FY2024 (FY) | 2024-12-31 | $5.7M | -$75.4M | -$60.5M | -$60.6M | $91.0M | — |
| FY2023 (FY) | 2023-12-31 | $1.7M | -$87.3M | -$81.2M | -$81.2M | — | — |
3. STTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs STTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Shattuck Labs Inc. (NASDAQ: STTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $5.72 (-1.46% 1D, market cap $574.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STTK ranks #915 in composite RQD confidence.
How does STTK compare to NGNE and EVO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STTK carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NGNE (Neurogene Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $576.7M) and EVO (Evotec SE) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $562.1M). Among the 5-stock peer group, STTK leads on earnings multiple (N/A) while STTK leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for STTK?
Per STTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680367), Shattuck Labs Inc. generated $1.0M in revenue (-82.5% YoY), -$48.8M in net income, and -$40.0M in free cash flow against $91.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is STTK trading relative to its 50-day, 200-day, and 52-week technical levels?
STTK last traded at $5.72 (-1.46% on volume of 676,331 shares), positioning the stock -8.92% below its 50-day simple moving average ($6.28) and -5.30% below its 200-day simple moving average ($6.04). Across its 52-week range of $1.72 to $8.33, STTK sits at the 60.5% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.01 to $6.43).
STTK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is STTK stock moving today?
Why STTK Stock slipped -1.46% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.